Key facts
- Immunera’s last known valuation is $37.5M (May 2025).
- It has raised $8.0M; the latest was Seed Round ($8.0M) in May 2025.
- Notable investors include Stanford University.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Immunera
- ·The full record, as it builds
Funding rounds
No funding rounds for Immunera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Immunera
Developer of a diagnostics startup intended to bring personalized medicine to autoimmune patients. The company offers gene sequencing and language models to analyze information provided by the body, utilizing this technology in blood test reports, enabling clients to make more informed decisions for patients with autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
- Sector
- Healthcare
- HQ
- Albany, NY, United States
- Founded
- 2025
- Website
- immunera.ai/
- Ownership
- Privately Held (backing)
Immunera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immunera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immunera in its N-PORT filings yet. We sweep new filings monthly.